Tools and resources

Adoption support resource – insights from the NHS

1 Introduction

1 Introduction

This adoption report was written to support the original NICE guidance evaluating Peristeen. The original Peristeen system was discontinued at the end of 2021. From January 2022, only Peristeen Plus is available to the NHS.

Peristeen Plus has minor functional changes. These include new connections, a new dial design, more intuitive symbols on the control unit, and a temperature indicator on the water bag. Peristeen Plus can also be used with either a balloon catheter or a cone catheter. This guidance review focuses on Peristeen Plus with the balloon catheter only.

These product changes did not alter any of the adoption considerations covered in this report. So, it remains valid and relevant to Peristeen Plus.

This resource provides practical information and advice on the NICE medical technologies guidance on Peristeen transanal irrigation system for managing bowel dysfunction.

NICE's adoption team worked with contributors in NHS organisations who use transanal irrigation systems, including Peristeen.

The information presented in this resource is intended to support the NHS in adopting, evaluating the impact of adopting, or further researching this technology. It is complementary to the medical technologies guidance and was not considered by the medical technologies advisory committee when developing its recommendations.

Peristeen (Coloplast) is a transanal irrigation system for managing bowel dysfunction. Further detail is described in the guidance.

The benefits of using Peristeen, as reported by the NHS staff involved in producing this resource, include:

  • Offering an additional treatment option for people with bowel dysfunction when conservative treatment has failed or is not suitable or when surgery is unlikely to improve symptoms.

  • Providing a less invasive option and reducing the need for surgery.

  • Improving people's quality of life, dignity and independence.

  • Reducing pain relief (including opioids) people take to help relieve symptoms and may reduce the need for bowel medicines (such as laxatives).

  • Facilitating transfer of people's care from surgeons' caseloads to a service led by a specialist clinician.

  • Reducing healthcare use (scheduled and unscheduled) including hospitalisations.


This page was last updated: